Bollard Group LLC Makes New $1.40 Million Investment in Nurix Therapeutics, Inc. $NRIX

Bollard Group LLC bought a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 122,782 shares of the company’s stock, valued at approximately $1,398,000. Bollard Group LLC owned approximately 0.16% of Nurix Therapeutics as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. E Fund Management Co. Ltd. bought a new stake in Nurix Therapeutics in the first quarter valued at about $122,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Nurix Therapeutics in the 2nd quarter worth approximately $141,000. KLP Kapitalforvaltning AS increased its holdings in shares of Nurix Therapeutics by 38.7% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 15,400 shares of the company’s stock valued at $175,000 after acquiring an additional 4,300 shares during the last quarter. Creative Planning acquired a new stake in shares of Nurix Therapeutics during the 2nd quarter valued at approximately $187,000. Finally, Hsbc Holdings PLC raised its position in shares of Nurix Therapeutics by 32.9% during the 1st quarter. Hsbc Holdings PLC now owns 16,095 shares of the company’s stock valued at $189,000 after acquiring an additional 3,988 shares in the last quarter.

Nurix Therapeutics Price Performance

NRIX opened at $18.09 on Friday. The stock’s 50 day moving average price is $12.58 and its 200 day moving average price is $11.40. The stock has a market cap of $1.39 billion, a P/E ratio of -6.09 and a beta of 1.87. Nurix Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $22.95.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Thursday, October 9th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.19). The company had revenue of $7.89 million during the quarter, compared to analyst estimates of $16.06 million. Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%. Equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Buying and Selling

In other Nurix Therapeutics news, insider Gwenn Hansen sold 4,087 shares of the company’s stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $12.80, for a total value of $52,313.60. Following the completion of the sale, the insider directly owned 76,751 shares in the company, valued at $982,412.80. This represents a 5.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Houte Hans Van sold 6,284 shares of Nurix Therapeutics stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $12.56, for a total value of $78,927.04. Following the transaction, the chief financial officer owned 37,592 shares in the company, valued at approximately $472,155.52. This trade represents a 14.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 13,501 shares of company stock valued at $171,305 over the last 90 days. 7.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on NRIX shares. Wall Street Zen lowered shares of Nurix Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, October 11th. Oppenheimer cut their target price on shares of Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating on the stock in a report on Friday, October 10th. Wells Fargo & Company decreased their target price on Nurix Therapeutics from $22.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, October 23rd. BTIG Research reiterated a “buy” rating and set a $27.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus set a $33.00 price target on Nurix Therapeutics in a report on Friday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.33.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.